Financial Data and Key Metrics Changes - For the full year 2025, net revenues reached $175.1 million, reflecting a 217% year-over-year growth [6] - Q4 revenue was $57.6 million, consistent with pre-release estimates and demonstrating 16% sequential quarterly growth [15] - Cash operating expenses for Q4 were $50.3 million, better than the guidance of less than $55 million [8][16] - The company reported a loss from operations of approximately $320K for Q4, a 95% improvement compared to Q3 [16] - Full-year cash operating expenses totaled approximately $284 million, at the low end of the guidance range [17] Business Line Data and Key Metrics Changes - Voquezna prescriptions filled exceeded 1.1 million for over 230,000 patients, with Q4 alone accounting for 273,000 prescriptions [11] - Covered prescriptions in Q4 grew 21% quarter-over-quarter, representing approximately 64% of total prescriptions filled [11] Market Data and Key Metrics Changes - The company targets a market of approximately 65 million patients suffering from gastroesophageal reflux, with 40% experiencing inadequate symptom relief from PPIs [11] - The sales organization is nearly fully staffed, with over 285 of 300 sales positions filled, indicating strong market engagement [12] Company Strategy and Development Direction - The company aims to achieve operating profitability beginning in Q3 2026 and cash flow positivity in 2027 [9][13] - A GI-focused strategy is expected to drive continued revenue growth, with 2026 revenue guidance set at $320 million-$345 million [5][23] - The company is exploring additional products and partnerships to expand its GI pipeline, with a focus on building relationships within the gastroenterology community [82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, citing strong momentum and a disciplined approach to expenses [10][25] - The company anticipates a steady growth pattern without a specific inflection point, focusing on consistent execution of its strategy [42] Other Important Information - The company successfully modified its term loan agreement, extending the maturity date to February 2029 and reducing interest expenses from 12% to 9.85% [18][19] - A shift in accounting classification will result in an estimated $17 million-$20 million change in 2026 net revenue reporting [23] Q&A Session Summary Question: Early signals from the strengthened sales force and strategy - Management noted consistent signs of momentum, with a high percentage of gastroenterologists already prescribing Voquezna and a focus on increasing writing frequency among physicians [30][31] Question: Dynamics of patients transitioning back to primary care - Management acknowledged an uplift in primary care prescribing volume but emphasized the current focus on gastroenterology [36] Question: Q1 expectations regarding sequential growth and Medicare coverage - Management indicated typical seasonality effects and incremental Medicare coverage but did not anticipate broad changes in coverage [51] Question: Impact of seasonality on prescription data - Management confirmed that seasonality is expected to follow historical patterns, with January and February typically being slower months [56] Question: Proportions of prescriptions filled through GoodRx and BlinkRx - Management reported that over half of prescriptions are routed through BlinkRx, with a small percentage utilizing GoodRx for cash pay options [60][63] Question: Long-term vision beyond Voquezna - The company is focused on consolidating its execution plan for Voquezna while exploring potential partnerships and additional products for the GI market [82]